FAF
NKTR icon

Fjarde Ap-fonden’s Nektar Therapeutics NKTR Stock Holding History

Fjarde Ap-fonden’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-1,485
Closed -$406K – 626
2019
Q3 		$406K Sell
1,485
-980
-40% -$359K 0.01% 608
2019
Q2 		$1.32M Sell
2,465
-800
-25% -$401K 0.02% 579
2019
Q1 		$1.65M Buy
3,265
+574
+21% +$340K 0.02% 556
2018
Q4 		$1.33M Sell
2,691
-560
-17% -$338K 0.02% 538
2018
Q3 		$2.97M Buy
3,251
+185
+6% +$158K 0.04% 469
2018
Q2 		$2.25M Buy
+3,066
New +$3.54M 0.03% 551

Other funds holding NKTR

Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return

Fjarde Ap-fonden's NKTR Position: Q4 2019 in Review

Fjarde Ap-fonden sold out of Nektar Therapeutics (NKTR) in Q4 2019, closing a stake of 1,485 shares — an estimated $406K sold.

Fjarde Ap-fonden first reported a position in NKTR in Q2 2018 and held it in 6 quarters. The position peaked at $2.97M in Q3 2018. 281 funds tracked by Wall St. Rank hold NKTR as of Q4 2019.

  • Fjarde Ap-fonden reported no remaining Nektar Therapeutics position as of Q4 2019 after selling out during the quarter.
  • Fjarde Ap-fonden sold 1,485 Nektar Therapeutics shares in Q4 2019, an estimated $406K.
  • Fjarde Ap-fonden first reported a position in Nektar Therapeutics in Q2 2018 and held it in 6 quarters.
  • Fjarde Ap-fonden's Nektar Therapeutics position peaked at $2.97M in Q3 2018.
  • 281 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q4 2019.

Based on Fjarde Ap-fonden's 13F filing for Q4 2019, filed 10 Feb 2020.